Toronto Stocks Advance; Docebo Shares Jump on 4Q Profit, Revenue Beat
By Adriano Marchese
Toronto-listed stocks were higher mid-trading on Friday, with the S&P/TSX Composite Index on track to cap off the shortened week slightly ahead.
Most sectors were in positive territory at noon, led by continued strong gains in tech, followed by commercial services and health tech. Of the few decliners in the session, materials, distribution services and consumer discretionary stocks were the main laggards.
Canada's S&P/TSX Composite Index was 0.38% higher at midday, at 21400.02, and the blue-chip S&P/TSX 60 rose by 0.48%, to 1294.54.
Docebo's shares were sharply up at midday, trading 16% higher, at 71.69 Canadian dollars (US$53.17), after the technology company's profit in the latest quarter roughly doubled on the back of stronger-than expected revenue.
Other market movers:
CI Financial's stock rose by 6%, to C$16.79, after the Canadian asset and wealth manager's fourth-quarter earnings beat expectations and it moved to launch a fresh share-buyback program.
Eldorado Gold shares were 9.1% lower, to C$13.84, after the resource company reported higher costs in its 2024 outlook and a lower four-year production outlook.
Shares in Hudbay Minerals were 6.2% higher, at C$7.66, after reporting a profit and higher revenue thanks to strong production in the fourth quarter. The company also said it expects copper production to continue to rise, while gold output is forecast to soften slightly.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 23, 2024 12:17 ET (17:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth